STOCK TITAN

Enanta Pharmaceuticals: ADAR1 reports 6% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Enanta Pharmaceuticals Inc. (ENTA) is the issuer in a Schedule 13G reporting that ADAR1 Capital Management, LLC and Daniel Schneeberger each beneficially own 1,733,320 common shares, or 6.0% of the class. Each reports shared voting and dispositive power over the same shares and zero sole voting or dispositive power. The percentage is based on 29,125,402 shares outstanding as of August 7, 2026.

Beneficially owned 1,733,320 shares Each reporting person reports the same shares.
Class ownership 6.0% Percentage reported for each reporting person.
Shares outstanding 29,125,402 shares As of August 7, 2026; used as the basis for the reported percentage.
beneficially owned regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 1,733,320.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 1,733,320.00"
investment adviser regulatory
"an investment adviser as described in Item 7"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ENTA shares did ADAR1 Capital Management and Daniel Schneeberger report?

Each reported beneficial ownership of 1,733,320 Enanta common shares, equal to 6.0% of the class.

Who directly owns the ENTA shares reported by ADAR1 Capital Management and Daniel Schneeberger?

The shares are owned directly by private investment funds managed by ADAR1 Capital Management. The statement identifies Daniel Schneeberger as ADAR1's sole manager and says the shares may be deemed indirectly beneficially owned by him.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





29251M106

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 1,733,320 shares of common stock, par value $0.01 per share ("Common Stock"), of Enanta Pharmaceuticals Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 29,125,402 shares of Common Stock outstanding as of August 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 1,733,320 shares of common stock, par value $0.01 per share ("Common Stock"), of Enanta Pharmaceuticals Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 29,125,402 shares of Common Stock outstanding as of August 7, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 12, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

Keep reading